These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 22899803)
1. Oritavancin does not induce Clostridium difficile germination and toxin production in hamsters or a human gut model. Freeman J; Marquis M; Crowther GS; Todhunter SL; Fawley WN; Chilton CH; Moeck G; Lehoux D; Wilcox MH J Antimicrob Chemother; 2012 Dec; 67(12):2919-26. PubMed ID: 22899803 [TBL] [Abstract][Full Text] [Related]
2. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH J Antimicrob Chemother; 2008 Nov; 62(5):1078-85. PubMed ID: 18772161 [TBL] [Abstract][Full Text] [Related]
3. Effectiveness of a short (4 day) course of oritavancin in the treatment of simulated Clostridium difficile infection using a human gut model. Chilton CH; Freeman J; Crowther GS; Todhunter SL; Wilcox MH J Antimicrob Chemother; 2012 Oct; 67(10):2434-7. PubMed ID: 22723601 [TBL] [Abstract][Full Text] [Related]
4. Activity of vancomycin against epidemic Clostridium difficile strains in a human gut model. Baines SD; O'Connor R; Saxton K; Freeman J; Wilcox MH J Antimicrob Chemother; 2009 Mar; 63(3):520-5. PubMed ID: 19112083 [TBL] [Abstract][Full Text] [Related]
5. Evaluation of the effect of oritavancin on Clostridium difficile spore germination, outgrowth and recovery. Chilton CH; Freeman J; Baines SD; Crowther GS; Nicholson S; Wilcox MH J Antimicrob Chemother; 2013 Sep; 68(9):2078-82. PubMed ID: 23759507 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. Freeman J; Baines SD; Jabes D; Wilcox MH J Antimicrob Chemother; 2005 Oct; 56(4):717-25. PubMed ID: 16143709 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. Crowther GS; Baines SD; Todhunter SL; Freeman J; Chilton CH; Wilcox MH J Antimicrob Chemother; 2013 Jan; 68(1):168-76. PubMed ID: 22966180 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model. Baines SD; Chilton CH; Crowther GS; Todhunter SL; Freeman J; Wilcox MH J Antimicrob Chemother; 2013 Aug; 68(8):1842-9. PubMed ID: 23557928 [TBL] [Abstract][Full Text] [Related]
10. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. Chilton CH; Freeman J; Crowther GS; Todhunter SL; Nicholson S; Wilcox MH J Antimicrob Chemother; 2012 Apr; 67(4):951-4. PubMed ID: 22279183 [TBL] [Abstract][Full Text] [Related]
11. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. Chilton CH; Crowther GS; Freeman J; Todhunter SL; Nicholson S; Longshaw CM; Wilcox MH J Antimicrob Chemother; 2014 Feb; 69(2):451-62. PubMed ID: 24003182 [TBL] [Abstract][Full Text] [Related]
12. Comparison of planktonic and biofilm-associated communities of Clostridium difficile and indigenous gut microbiota in a triple-stage chemostat gut model. Crowther GS; Chilton CH; Todhunter SL; Nicholson S; Freeman J; Baines SD; Wilcox MH J Antimicrob Chemother; 2014 Aug; 69(8):2137-47. PubMed ID: 24788662 [TBL] [Abstract][Full Text] [Related]
13. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. Freeman J; Baines SD; Saxton K; Wilcox MH J Antimicrob Chemother; 2007 Jul; 60(1):83-91. PubMed ID: 17483547 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. Ochsner UA; Bell SJ; O'Leary AL; Hoang T; Stone KC; Young CL; Critchley IA; Janjic N J Antimicrob Chemother; 2009 May; 63(5):964-71. PubMed ID: 19251726 [TBL] [Abstract][Full Text] [Related]
15. Mixed infection by Clostridium difficile in an in vitro model of the human gut. Baines SD; Crowther GS; Todhunter SL; Freeman J; Chilton CH; Fawley WN; Wilcox MH J Antimicrob Chemother; 2013 May; 68(5):1139-43. PubMed ID: 23354280 [TBL] [Abstract][Full Text] [Related]
16. Association of Fidaxomicin with C. difficile Spores: Effects of Persistence on Subsequent Spore Recovery, Outgrowth and Toxin Production. Chilton CH; Crowther GS; Ashwin H; Longshaw CM; Wilcox MH PLoS One; 2016; 11(8):e0161200. PubMed ID: 27556739 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. Chilton CH; Crowther GS; Todhunter SL; Nicholson S; Freeman J; Chesnel L; Wilcox MH J Antimicrob Chemother; 2014 Sep; 69(9):2426-33. PubMed ID: 24816211 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. Baines SD; Noel AR; Huscroft GS; Todhunter SL; O'Connor R; Hobbs JK; Freeman J; Lovering AM; Wilcox MH J Antimicrob Chemother; 2011 Jul; 66(7):1537-46. PubMed ID: 21504940 [TBL] [Abstract][Full Text] [Related]
20. A combination of the probiotic and prebiotic product can prevent the germination of Clostridium difficile spores and infection. Rätsep M; Kõljalg S; Sepp E; Smidt I; Truusalu K; Songisepp E; Stsepetova J; Naaber P; Mikelsaar RH; Mikelsaar M Anaerobe; 2017 Oct; 47():94-103. PubMed ID: 28465256 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]